KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Liabilities: 2018-2025

Historic Total Liabilities for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $95.7 million.

  • Castle Biosciences' Total Liabilities rose 30.24% to $95.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.7 million, marking a year-over-year increase of 30.24%. This contributed to the annual value of $75.4 million for FY2024, which is 21.47% up from last year.
  • Castle Biosciences' Total Liabilities amounted to $95.7 million in Q3 2025, which was up 7.15% from $89.4 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Total Liabilities peaked at $95.7 million during Q3 2025, and registered a low of $18.7 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $62.1 million (2023), whereas its average is $65.1 million.
  • In the last 5 years, Castle Biosciences' Total Liabilities crashed by 55.34% in 2021 and then spiked by 151.21% in 2022.
  • Quarterly analysis of 5 years shows Castle Biosciences' Total Liabilities stood at $50.8 million in 2021, then decreased by 5.22% to $48.2 million in 2022, then grew by 28.83% to $62.1 million in 2023, then grew by 21.47% to $75.4 million in 2024, then spiked by 30.24% to $95.7 million in 2025.
  • Its Total Liabilities stands at $95.7 million for Q3 2025, versus $89.4 million for Q2 2025 and $61.4 million for Q1 2025.